BACKGROUND: Lymph node metastasis is an important indicator of oncologic outcome for patients with rectal cancer. Identifying predictive biomarkers of lymph node metastasis could therefore be clinically useful. OBJECTIVE: The aim of this study was to assess whether chromosomal copy number alterations can assist in predicting persistent lymph node metastasis in patients with locally advanced rectal cancer treated with preoperative chemoradiation therapy. DESIGN: This is a nonrandomized, prospective phase II study. SETTING: This study took place in a multi-institutional setting. PATIENTS: Ninety-five patients with stage II (cT3-4, cN0) or stage III (any cT, cN1-2) rectal cancer were included. INTERVENTION: Patients were treated with preoperative chemoradiation therapy followed by total mesorectal excision. Pretreatment biopsy tumor DNA and surgical margin control DNA were extracted and analyzed by oligonucleotide array-based comparative genomic hybridization. Chromosomal copy number alterations were correlated with persistent lymph node metastasis. Finally, a model for predicting persistent lymph node metastasis was built. MAIN OUTCOME MEASURES: The primary outcomes assessed were whether chromosomal copy number alterations are associated with persistent lymph node metastasis in patients with rectal cancer and the accuracy of oligonucleotide array-based comparative genomic hybridization for predicting lymph node metastasis. RESULTS: Twenty-five of 95 (26%) patients had lymph node metastasis after chemoradiation. Losses of 28 chromosomal regions, most notably in chromosome 4, were significantly associated with lymph node metastasis. Our predictive model contained 65 probes and predicted persistent lymph node metastasis with 68% sensitivity, 93% specificity, and positive and negative predictive values of 77% and 89%. The use of this model accurately predicted lymph node status (positive or negative) after chemoradiation therapy in 82 of 95 patients (86%). LIMITATIONS: The patient cohort was not completely homogeneous, which may have influenced their clinical outcome. In addition, although we performed rigorous, statistically sound internal validation, external validation will be important to further corroborate our findings. CONCLUSIONS: Copy number alterations can help identify patients with rectal cancer who are at risk of lymph node metastasis after chemoradiation.
BACKGROUND:Lymph node metastasis is an important indicator of oncologic outcome for patients with rectal cancer. Identifying predictive biomarkers of lymph node metastasis could therefore be clinically useful. OBJECTIVE: The aim of this study was to assess whether chromosomal copy number alterations can assist in predicting persistent lymph node metastasis in patients with locally advanced rectal cancer treated with preoperative chemoradiation therapy. DESIGN: This is a nonrandomized, prospective phase II study. SETTING: This study took place in a multi-institutional setting. PATIENTS: Ninety-five patients with stage II (cT3-4, cN0) or stage III (any cT, cN1-2) rectal cancer were included. INTERVENTION: Patients were treated with preoperative chemoradiation therapy followed by total mesorectal excision. Pretreatment biopsy tumor DNA and surgical margin control DNA were extracted and analyzed by oligonucleotide array-based comparative genomic hybridization. Chromosomal copy number alterations were correlated with persistent lymph node metastasis. Finally, a model for predicting persistent lymph node metastasis was built. MAIN OUTCOME MEASURES: The primary outcomes assessed were whether chromosomal copy number alterations are associated with persistent lymph node metastasis in patients with rectal cancer and the accuracy of oligonucleotide array-based comparative genomic hybridization for predicting lymph node metastasis. RESULTS: Twenty-five of 95 (26%) patients had lymph node metastasis after chemoradiation. Losses of 28 chromosomal regions, most notably in chromosome 4, were significantly associated with lymph node metastasis. Our predictive model contained 65 probes and predicted persistent lymph node metastasis with 68% sensitivity, 93% specificity, and positive and negative predictive values of 77% and 89%. The use of this model accurately predicted lymph node status (positive or negative) after chemoradiation therapy in 82 of 95 patients (86%). LIMITATIONS: The patient cohort was not completely homogeneous, which may have influenced their clinical outcome. In addition, although we performed rigorous, statistically sound internal validation, external validation will be important to further corroborate our findings. CONCLUSIONS: Copy number alterations can help identify patients with rectal cancer who are at risk of lymph node metastasis after chemoradiation.
Authors: Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab Journal: N Engl J Med Date: 2004-10-21 Impact factor: 91.245
Authors: Samantha K Hendren; Brenda I O'Connor; Maria Liu; Tracey Asano; Zane Cohen; Carol J Swallow; Helen M Macrae; Robert Gryfe; Robin S McLeod Journal: Ann Surg Date: 2005-08 Impact factor: 12.969
Authors: R Arribas; M Ribas; R A Risques; L Masramon; S Tórtola; E Marcuello; G Aiza; R Miró; G Capellà; M A Peinado Journal: Clin Cancer Res Date: 1999-11 Impact factor: 12.531
Authors: K C M J Peeters; C J H van de Velde; J W H Leer; H Martijn; J M C Junggeburt; E Klein Kranenbarg; W H Steup; T Wiggers; H J Rutten; C A M Marijnen Journal: J Clin Oncol Date: 2005-09-01 Impact factor: 44.544
Authors: Chieu B Diep; Manuel R Teixeira; Lin Thorstensen; Johan N Wiig; Mette Eknaes; Jahn M Nesland; Karl-Erik Giercksky; Bertil Johansson; Ragnhild A Lothe Journal: Mol Cancer Date: 2004-02-23 Impact factor: 27.401
Authors: Raphael Pelossof; Oliver S Chow; Lauren Fairchild; J Joshua Smith; Manu Setty; Chin-Tung Chen; Zhenbin Chen; Fumiko Egawa; Karin Avila; Christina S Leslie; Julio Garcia-Aguilar Journal: Genes Chromosomes Cancer Date: 2016-04 Impact factor: 5.006
Authors: T Sprenger; H Rothe; T Beissbarth; L-C Conradi; A Kauffels; K Homayounfar; C L Behnes; C Rödel; T Liersch; M Ghadimi Journal: Chirurg Date: 2016-07 Impact factor: 0.955
Authors: Elaine S Tan; Todd C Knepper; Xuefeng Wang; Jennifer B Permuth; Liang Wang; Jason B Fleming; Hao Xie Journal: Cancers (Basel) Date: 2022-04-29 Impact factor: 6.575
Authors: Inès J Goossens-Beumer; Jan Oosting; Wim E Corver; Marjolein J F W Janssen; Bart Janssen; Wilbert van Workum; Eliane C M Zeestraten; Cornelis J H van de Velde; Hans Morreau; Peter J K Kuppen; Tom van Wezel Journal: BMC Genomics Date: 2015-06-06 Impact factor: 3.969